Researchers find that only 2.4% of prescriptions for 90 “substitutable” drugs were for brand-name drugs yet they accounted 21.2% of the expenditures on those drugs.
Substituting brand-name drugs with generics is a well-trodden path to considerable drug savings. But findings reported today show that when it comes to cardiovascular therapies, a small minority of physicians prescribing a relatively small number of brand-name drugs with generic substitutions are squandering the opportunity to realize savings from brand-to-generic substitution.
Results from a cross-sectional study of a Medicare Part D database showed that a large proportion (300,275 of 418,836,or 71.7%) of clinicians prescribed only generics. But a relatively small proportion (34,239 of 418,836, or 8.2%) of physicians prescribed brand-name drugs instead of less expensive generics that would have resulted in 50% of the potential savings if they had prescribed generics instead.
Overall, the researchers calculated that generic substitution for brand-name cardiovascular drugs would have saved $641 million in 2017, which works out to be about 2.7% of the $22.9 billion spent on 169 cardiovascular drugs in Medicare Part D that year. They calculated that more than half ($395 million, or 61.6%) of that potential savings would have resulted from swapping out brand-name versions for cheaper generics of just three drugs: ezetimibe (Zetia is the brand-named drug), rosuvastatin (Crestor and Ezalior) and an ezetimibe-simvastatin combination (Vytorin).
The researchers, led by Iris Ma, M.D., of California Pacific Medical Center in San Francisco, narrowed down the 169 cardiovascular drugs down to 90 with generic substitutes. Of the 856 monthly fills of prescriptions for those 90 drugs, only a small fraction — 2.4% — were for brand-name drugs, a reflection of how common generic drugs have become. However, a disproportionate share — 21.2%, or $2.3 billion — share of the $11 billion spent on those “substitutable” cardiovascular drugs was for brand-name drugs.
Ma and her colleagues calculated that substituting brand-name cardiovascular drugs for lower-cost equivalents would have resulted in $1.3 billion in Part D savings. Once rebates were factored, that savings shrunk to $641 million. Their calculations also showed that replacing brand-name cardiovascular drugs for generics would have resulted in a reduction of $135 million in patient out-of-pocket costs.
The researchers looked at the effect of state-level generic switching law. According to Ma and her co-investigators, 20 states mandate generic substitution if the prescriber did not specify “dispense as written.” Twenty-six state and the District of Columbia require either explicit consent or patient right to refuse generic swap. Although they found some state-by-state in generic prescribing and the potential for savings, they did not find that the variation was associated with state law. “Our findings,” they wrote, “suggest alternate drivers of the variations observed in brand-name cardiovascular fills, such as patient preference or clinician prescribing habits, rather than state laws.”
They also noted that over half of the potential savings from brand-name to generic were from prescriptionsby clinicians who prescribed those drugs 10 or fewer times in the year. They saw that lack of generic substitution by low-volume prescribers reinforces the importance of system-level interventions to move prescriptions over to generics.
Ma and her colleagues reported their results in the Circulation: Cardiovascular Quality and Outcomes.
Optimize Your Healthcare Payments with Optum Financial
April 29th 2025Discover how Optum Financial is revolutionizing healthcare payments in our latest whitepaper. Learn how transitioning to electronic payments can reduce administrative costs, streamline claims processing and enhance security.
Read More
Conversations With Perry and Friends
April 14th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. His guest this episode is John Baackes, the former CEO of L.A. Care Health Plan.
Listen
Healthcare hasn't been a priority of the second Trump administration so far, panelists at the Asembia agreed. Medicaid may loom large, though, as the administration and congressional Republicans look for ways to slash government spending as a way of offsetting major tax cuts.
Read More
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
What 5 Managed Care Trends Experts Say You’re Not Watching Closely Enough
April 29th 2025Managed Healthcare Executive asked several experts in healthcare and managed care to share the trends they think the industry is overlooking. From rising costs and data challenges to shifts in how care is delivered, these are the issues that could have a major impact — and deserve a closer look.
Read More